TY - JOUR
T1 - Pancreatic neuroendocrine neoplasms
T2 - The latest surgical and medical treatment strategies based on the current World Health Organization classification
AU - Ishida, Hirotaka
AU - Lam, Alfred King Yin
N1 - Funding Information:
The research is supported by funding from Mr Nigel Chamier AO DUniv, Chair of Menzies Health Institute Queensland Advisory Board, Gold Coast, Australia .
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2020/1
Y1 - 2020/1
N2 - There is a recent update in WHO classification of pancreatic neuroendocrine neoplasms (PanNENs). Our aim is to analyse the latest management for patients with PanNENs according to the current classification of these neoplasms. The primary treatment is curative surgery and the surgical procedures depend on size, location, and histopathology of the tumour. Even if tumour has metastases, debulking surgery or resection of the primary lesion could improve the prognosis of these patients. Systemic medication is indicated in patients with unresectable primary and/or distant metastatic lesions. As new antineoplastic agents have been approved in the last decade for the treatment of PanNENs, the clinical outcome is improving. However, the appropriate selection or the effective combination of drugs has not been fully established. To conclude, management of PanNENs depends on various factors and further development of treatment strategies is required for improvement of survival outcome of patients with PanNENs.
AB - There is a recent update in WHO classification of pancreatic neuroendocrine neoplasms (PanNENs). Our aim is to analyse the latest management for patients with PanNENs according to the current classification of these neoplasms. The primary treatment is curative surgery and the surgical procedures depend on size, location, and histopathology of the tumour. Even if tumour has metastases, debulking surgery or resection of the primary lesion could improve the prognosis of these patients. Systemic medication is indicated in patients with unresectable primary and/or distant metastatic lesions. As new antineoplastic agents have been approved in the last decade for the treatment of PanNENs, the clinical outcome is improving. However, the appropriate selection or the effective combination of drugs has not been fully established. To conclude, management of PanNENs depends on various factors and further development of treatment strategies is required for improvement of survival outcome of patients with PanNENs.
KW - Drug
KW - Pancreas
KW - Pancreatic neuroendocrine carcinoma
KW - Pancreatic neuroendocrine neoplasm
KW - Pancreatic neuroendocrine tumour
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85076531524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076531524&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2019.102835
DO - 10.1016/j.critrevonc.2019.102835
M3 - Review article
C2 - 31864179
AN - SCOPUS:85076531524
SN - 1040-8428
VL - 145
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 102835
ER -